Evotec will provide discovery and preclinical development services and Debiopharm will be responsible for clinical development. Evotec will receive R&D funding and payments based on clinical, regulatory and commercial milestones, as well as royalties on sales of resulting products.
Dr. Cord Dohrmann, chief scientific officer of Evotec, said, "We are very excited about this innovative collaboration. It combines our proven discovery platform with Debiopharm's ability to advance projects through clinical development in a highly efficient manner while sharing risks and rewards of Evotec's Target X project. There is compelling science around the target and we are confident that we will be able to position highly competitive compounds in this field that hold great potential for difficult to treat cancers."
"This is a fine example of how drug discovery and development will be in the future; a mixture of complementarities looking to bring to a defined population of patients a drug that will change the outcome of disease,” said Andres McAllister, chief scientific officer, Debiopharm International SA.